In the search for the first disease-modifying therapy for Parkinson disease, drug developers are advancing α-synuclein-targeted agents into proof-of-concept clinical trials.

中文翻译：

---

归一化神经退行性α-突触核蛋白

在寻找针对帕金森氏病的首个疾病缓解疗法时，药物开发人员正在将以α-突触核蛋白为靶标的药物推进概念验证的临床试验。